EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
Portfolio Pulse from Vandana Singh
JonesResearch initiates coverage of EyePoint Pharmaceuticals with a Buy rating and a $26 price target, predicting potential $870M sales by 2035 for its lead asset EYP-1901 for age-related macular degeneration (AMD). The company is conducting a Phase 2 trial and expects results in December 2023.
June 14, 2023 | 7:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron Pharmaceuticals' Eylea, a standard-of-care VEGF-A inhibitor for wet AMD, is mentioned as one of the few therapies currently available in the market.
The mention of Regeneron's Eylea as one of the few available wet AMD therapies indicates that EyePoint's EYP-1901 could be a potential competitor in the market. If EYP-1901 proves successful, it may impact Regeneron's market share in the wet AMD space.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Roche Holding's Lucentis, a standard-of-care VEGF-A inhibitor for wet AMD, is mentioned as one of the few therapies currently available in the market.
The mention of Roche's Lucentis as one of the few available wet AMD therapies indicates that EyePoint's EYP-1901 could be a potential competitor in the market. If EYP-1901 proves successful, it may impact Roche's market share in the wet AMD space.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
EyePoint Pharmaceuticals receives a Buy rating and a $26 price target from JonesResearch, with potential $870M sales by 2035 for its lead asset EYP-1901 for AMD treatment.
The Buy rating and $26 price target from JonesResearch indicate a positive outlook for EyePoint Pharmaceuticals. The potential $870M sales by 2035 for EYP-1901, a first-in-class maintenance therapy for AMD, suggest significant growth potential for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100